138 related articles for article (PubMed ID: 35925536)
1. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.
Adam MA; Glencer A; AlMasri S; Winters S; Bahary N; Singhi A; Lee KK; Paniccia A; Zureikat AH
Ann Surg Oncol; 2023 Jan; 30(1):165-174. PubMed ID: 35925536
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
4. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
5. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
6. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
7. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
Hester CA; Dogeas E; Augustine MM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Yopp AC
J Surg Oncol; 2019 Mar; 119(3):303-317. PubMed ID: 30561818
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
9. Impact of Staging Concordance and Downstaging After Neoadjuvant Therapy on Survival Following Resection of Intrahepatic Cholangiocarcinoma: A Bayesian Analysis.
Alaimo L; Moazzam Z; Lima HA; Endo Y; Woldesenbet S; Ejaz A; Cloyd J; Guglielmi A; Ruzzenente A; Pawlik TM
Ann Surg Oncol; 2023 Aug; 30(8):4799-4808. PubMed ID: 37029867
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma.
Silver CM; Joung RH; Logan CD; Benson AB; Mahalingam D; D'Angelica MI; Bentrem DJ; Yang AD; Bilimoria KY; Merkow RP
J Surg Oncol; 2023 Jan; 127(1):90-98. PubMed ID: 36194064
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.
Zhang C; Lizalek JM; Dougherty C; Westmark DM; Klute KA; Reames BN
Ann Surg Oncol; 2024 Feb; 31(2):792-803. PubMed ID: 37952021
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma.
Kamarajah SK; Markar SR; Phillips AW; Kunene V; Fackrell D; Salti GI; Dahdaleh FS; Griffiths EA
Eur J Surg Oncol; 2022 Sep; 48(9):1980-1987. PubMed ID: 35718676
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score-weighted analysis.
Marqueen KE; Moshier E; Buckstein M; Ang C
Int J Cancer; 2021 Jul; 149(1):177-185. PubMed ID: 33634858
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
17. Evolving management of early stage pancreatic adenocarcinoma in older patients.
Nassoiy S; Christopher W; Marcus R; Keller J; Weiss J; Chang SC; Essner R; Foshag L; Fischer T; Goldfarb M
Am J Surg; 2023 Jan; 225(1):212-219. PubMed ID: 36058752
[TBL] [Abstract][Full Text] [Related]
18. Upfront versus resection after neoadjuvant chemotherapy for pancreatic adenocarcinomas with venous contact: comparative analysis of operative and survival outcomes.
Addeo P; Cusumano C; Dufour P; Avérous G; Bachellier P
Surgery; 2022 Aug; 172(2):702-707. PubMed ID: 35232605
[TBL] [Abstract][Full Text] [Related]
19. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
Ratnayake B; Savastyuk AY; Nayar M; Wilson CH; Windsor JA; Roberts K; French JJ; Pandanaboyana S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640720
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP.
Krell RW; McNeil LR; Yanala UR; Are C; Reames BN
Ann Surg Oncol; 2021 Jul; 28(7):3810-3822. PubMed ID: 33386542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
